深度热疗联合吉西他滨放化疗或改善不可切除局部晚期胰腺癌生存
该研究基于HEATPAC II期试验方案,纳入9例不可切除局部晚期胰腺癌患者,接受4周期FOLFORINOX化疗后行吉西他滨为基础的放化疗(56 Gy)联合同步每周深度热疗,再行8周期FOLFORINOX化疗。结果显示1例3级相关毒性,2例肿瘤变为可切除,中位总生存24个月,1年总生存率100%。
要点
- 深度热疗联合同步放化疗在9例局部晚期胰腺癌中可行。
- 中位总生存24个月,1年总生存率100%。
- 仅报告1例3级相关毒性,2例转为可切除。
核心结论
- 在9例不可切除局部晚期胰腺癌患者中,深度热疗联合吉西他滨为基础的放化疗是可行的。
研究设计与样本
- 基于HEATPAC II期试验方案的单组研究,纳入9例局部晚期胰腺癌患者。
- 治疗方案为4周期FOLFORINOX化疗后行吉西他滨为基础的放化疗至56 Gy联合同步每周深度热疗,再行8周期FOLFORINOX化疗。
主要发现
- 报告1例3级相关毒性。
- 2例肿瘤变为可切除。
- 中位总生存为24个月,1年总生存率为100%。
关键数值与推荐
- 放化疗剂量为56 Gy,联合吉西他滨为基础方案及每周深度热疗。
- FOLFORINOX化疗共4周期(放化疗前)和8周期(放化疗后)。
临床怎么用
- 对于不可切除局部晚期胰腺癌,可考虑在吉西他滨为基础放化疗基础上联合深度热疗,但需在临床研究框架内评估可行性。
局限性
- 样本量仅9例,为单组设计,未设对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Driven by the current unsatisfactory outcomes for patients with locally advanced pancreatic cancer (LAPC), a biologically intensified clinical protocol was developed to explore the feasibility and efficacy of FOLFORINOX chemotherapy followed by deep hyperthermia concomitant with chemoradiation and subsequent FOLFORINOX chemotherapy in patients with LAPC. METHODS: Nine patients with LAPC were treated according to the HEATPAC Phase II trial protocol which consists of 4 cycles of FOLFORINOX chemotherapy followed by gemcitabine-based chemoradiation to 56 Gy combined with weekly deep hyperthermia and then a further 8 cycles of FOLFORINOX chemotherapy. RESULTS: One grade three related toxicity was reported and two tumours became resectable. The median overall survival was 24 months and 1 year overall survival was 100%. CONCLUSIONS: Intensification of chemoradiation with deep hyperthermia was feasible in nine consecutive patients with LAPC.
引用
- Rogers SJ, Datta NR, Puric E, et al. The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas. Clin Transl Radiat Oncol. 2021. PMID: 33598571. doi:10.1016/j.ctro.2021.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。